Summit Therapeutics Inc.
SMMT
$25.18
$1.225.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 84.79% | 99.29% | 118.71% | 60.93% | 28.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 76.02% | 90.01% | 96.21% | 91.57% | 95.91% |
| Total Operating Expenses | 104.95% | 137.78% | 176.72% | 130.70% | 93.34% |
| Operating Income | -104.95% | -137.78% | -176.72% | -131.52% | -94.83% |
| Income Before Tax | -107.50% | 64.01% | 67.09% | 72.95% | 80.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -107.50% | 64.01% | 67.09% | 72.95% | 80.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.50% | 64.01% | 67.09% | 72.95% | 80.65% |
| EBIT | -104.95% | -137.78% | -176.72% | -131.52% | -94.83% |
| EBITDA | -105.11% | -138.21% | -178.58% | -134.18% | -98.08% |
| EPS Basic | -99.70% | 80.00% | 82.21% | 86.23% | 90.88% |
| Normalized Basic EPS | -86.97% | -78.39% | -67.86% | 21.43% | 59.86% |
| EPS Diluted | -110.98% | 79.10% | 81.76% | 85.96% | 90.89% |
| Normalized Diluted EPS | -86.97% | -78.39% | -67.86% | 21.43% | 59.86% |
| Average Basic Shares Outstanding | 4.01% | 16.15% | 38.50% | 87.31% | 210.49% |
| Average Diluted Shares Outstanding | 4.01% | 16.15% | 38.50% | 87.31% | 210.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |